https://www.phacilitate.com/advanced-therapies-europe-20262026-04-21T08:29:18Zhttps://www.phacilitate.com/advanced-therapies-europe-2026/registration-networking2026-04-20T14:34:57Zhttps://www.phacilitate.com/advanced-therapies-europe-2026/welcome-state-of-play-advanced-therapies-in-20262026-04-20T14:34:57Zhttps://www.phacilitate.com/advanced-therapies-europe-2026/panel-what-it-takes-to-fund-advanced-therapies-in-20262026-04-20T14:34:57Zhttps://www.phacilitate.com/advanced-therapies-europe-2026/break2026-04-20T14:34:59Zhttps://www.phacilitate.com/advanced-therapies-europe-2026/panel-alternative-funding-models-and-capital-structures-for-biotech2026-04-20T14:34:59Zhttps://www.phacilitate.com/advanced-therapies-europe-2026/welcome-address2026-04-20T14:35:00Zhttps://www.phacilitate.com/advanced-therapies-europe-2026/break-12026-04-20T14:35:00Zhttps://www.phacilitate.com/advanced-therapies-europe-2026/spotlight-from-first-in-class-to-phase-iii-what-weve-learnt-about-the-future-of-allogeneic-cell-therapy2026-04-20T14:35:00Zhttps://www.phacilitate.com/advanced-therapies-europe-2026/lunch2026-04-20T14:35:00Zhttps://www.phacilitate.com/advanced-therapies-europe-2026/spotlight-aav-manufacturing-reality-check-what-broke-at-scale-what-had-to-change-and-what-wed-design-differently-today2026-04-20T14:35:01Zhttps://www.phacilitate.com/advanced-therapies-europe-2026/fireside-chat-across-the-finish-line-what-fda-bla-reviews-really-test-and-where-european-cgt-teams-are-most-often-surprised2026-04-20T14:35:01Zhttps://www.phacilitate.com/advanced-therapies-europe-2026/break-22026-04-20T14:35:02Zhttps://www.phacilitate.com/advanced-therapies-europe-2026/spotlight-engineering-safety-at-scale-how-next-generation-aav-manufacturing-is-tackling-yield-consistency-and-toxicity-risk-together2026-04-20T14:35:02Zhttps://www.phacilitate.com/advanced-therapies-europe-2026/spotlight-bridging-proof-and-progress-why-promising-cgts-still-stall-and-how-smarter-trial-infrastructure-unlocks-flow2026-04-20T14:35:02Zhttps://www.phacilitate.com/advanced-therapies-europe-2026/panel-cgt-clinical-trials-at-pace-whats-accelerating-whats-stuck-and-how-europe-turns-trials-into-treatments2026-04-20T14:35:02Zhttps://www.phacilitate.com/advanced-therapies-europe-2026/spotlight-scaling-the-in-vivo-moment-why-delivery-data-and-execution-now-decide-how-far-and-how-fast-programmes-progress2026-04-20T14:35:03Zhttps://www.phacilitate.com/advanced-therapies-europe-2026/fireside-chat-aav-at-scale-without-compromise-how-the-field-is-fixing-manufacturing-bottlenecks-and-toxicity-risk-without-slowing-clinical-momentum2026-04-20T14:35:03Zhttps://www.phacilitate.com/advanced-therapies-europe-2026/fireside-chat-data-that-holds-up-under-pressure-how-to-generate-phase-i-ii-efficacy-data-that-survives-scale-up-scrutiny-and-value-inflection2026-04-20T14:35:03Zhttps://www.phacilitate.com/advanced-therapies-europe-2026/spotlight-in-vivo-by-design-what-had-to-change-to-move-from-promise-to-predictable-clinical-signal2026-04-20T14:35:03Zhttps://www.phacilitate.com/advanced-therapies-europe-2026/panel-the-in-vivo-inflection-from-breakthrough-to-clinical-momentum-how-far-and-how-fast-can-this-wave-go2026-04-20T14:35:04Zhttps://www.phacilitate.com/advanced-therapies-europe-2026/debate-not-all-money-is-equal2026-04-20T14:35:05Zhttps://www.phacilitate.com/advanced-therapies-europe-2026/spotlight-building-for-the-long-game-what-it-really-takes-to-industrialise-cell-gene-therapy-at-scale2026-04-20T14:35:05Zhttps://www.phacilitate.com/advanced-therapies-europe-2026/panel-from-scaled-to-standard-of-care-commercialising-cgts-across-europes-fragmented-health-systems2026-04-20T14:35:05Zhttps://www.phacilitate.com/advanced-therapies-europe-2026/spotlight-why-scaling-cgt-production-is-no-longer-the-hard-part-and-what-now-determines-commercial-success2026-04-20T14:35:05Zhttps://www.phacilitate.com/advanced-therapies-europe-2026/panel-the-patient-precedence-what-patients-are-still-telling-us-about-access-failures-and-what-must-change-next2026-04-20T14:35:06Zhttps://www.phacilitate.com/advanced-therapies-europe-2026/panel-winning-the-next-wave-of-atmp-rd-what-europe-must-resolve-to-compete-on-speed-scale-and-return2026-04-20T14:35:06Zhttps://www.phacilitate.com/advanced-therapies-europe-2026/panel-designing-cgts-in-the-age-of-agentic-ai-how-to-accelerate-discovery-and-development-without-losing-regulatory-control2026-04-20T14:35:07Zhttps://www.phacilitate.com/advanced-therapies-europe-2026/panel-differentiation-or-bust-how-to-stand-out-in-a-saturated-market2026-04-20T14:35:07Zhttps://www.phacilitate.com/advanced-therapies-europe-2026/fireside-chat-what-investment-ready-looks-like-in-20262026-04-20T14:35:08Zhttps://www.phacilitate.com/advanced-therapies-europe-2026/innovation-exchange2026-04-20T14:35:08Zhttps://www.phacilitate.com/advanced-therapies-europe-2026/break-32026-04-20T14:35:09Zhttps://www.phacilitate.com/advanced-therapies-europe-2026/spotlight-off-the-shelf-is-working-now-what-has-to-change-to-scale-it-responsibly2026-04-20T14:35:09Zhttps://www.phacilitate.com/advanced-therapies-europe-2026/spotlight-off-the-shelf-only-works-if-the-system-can-absorb-it-what-delivery-partnerships-and-hospital-readiness-must-look-like-next2026-04-20T14:35:10Zhttps://www.phacilitate.com/advanced-therapies-europe-2026/panel-access-is-the-real-innovation-how-europe-turns-allogeneic-breakthroughs-into-therapies-patients-can-actually-receive2026-04-20T14:35:10Zhttps://www.phacilitate.com/advanced-therapies-europe-2026/lunch-12026-04-20T14:35:10Zhttps://www.phacilitate.com/advanced-therapies-europe-2026/panel-europes-atmp-rulebook-reset-the-12-month-pathway-from-fragmented-rules-to-trusted-eu-execution2026-04-20T14:35:10Zhttps://www.phacilitate.com/advanced-therapies-europe-2026/spotlight-lessons-and-legacy-from-europes-most-ambitious-decentralised-car-t-model2026-04-20T14:35:11Zhttps://www.phacilitate.com/advanced-therapies-europe-2026/spotlight-innovation-exchange-winner-2025-kindling-bio-where-are-they-now2026-04-20T14:35:11Zhttps://www.phacilitate.com/advanced-therapies-europe-2026/panel-modalities-and-markets-at-the-crossroads-where-advanced-therapies-go-next-and-how-europe-chooses-to-compete2026-04-20T14:35:12Zhttps://www.phacilitate.com/advanced-therapies-europe-2026/spotlight-engineering-cost-out-of-cmc-where-process-platform-and-production-choices-change-the-economics2026-04-20T14:35:12Zhttps://www.phacilitate.com/advanced-therapies-europe-2026/spotlight-cogs-comes-first-what-broke-when-we-tried-to-scale-and-what-we-changed-before-it-was-too-late2026-04-20T14:35:13Zhttps://www.phacilitate.com/advanced-therapies-europe-2026/panel-cmc-cost-of-goods-the-red-flag-we-cant-ignore-how-advanced-therapies-fic-the-economics-before-scale-makes-it-worse2026-04-20T14:35:13Zhttps://www.phacilitate.com/advanced-therapies-europe-2026/panel-from-bottleneck-to-enabler-rethinking-qc-strategies-for-cell-and-gene-therapy-manufacturing2026-04-22T08:11:33Zhttps://www.phacilitate.com/advanced-therapies-europe-2026/lunch-22026-04-22T13:55:35Zhttps://www.phacilitate.com/advanced-therapies-europe-2026/opening-welcome2026-04-22T15:19:23Zhttps://www.phacilitate.com/advanced-therapies-europe-2026/fireside-chat-weve-heard-the-challenges-now-what-are-we-changing2026-04-22T15:19:23Zhttps://www.phacilitate.com/advanced-therapies-europe-2026/how-i-did-it-real-stories-from-building-funding-and-leading2026-04-22T15:19:24Zhttps://www.phacilitate.com/advanced-therapies-europe-2026/networking-break2026-04-22T15:19:24Zhttps://www.phacilitate.com/advanced-therapies-europe-2026/panel-ask-us-anything-solving-the-hard-problems-from-barrier-to-action2026-04-22T15:19:25Zhttps://www.phacilitate.com/advanced-therapies-europe-2026/whos-in-the-room-speed-networking-activation-session2026-04-22T15:19:25Zhttps://www.phacilitate.com/advanced-therapies-europe-2026/closing-statement-from-insight-to-action-what-happens-next2026-04-22T15:19:25Z